Astonea Labs IPO - Day 3 Subscription at 1.79 Times

Astonea Labs' initial public offering (IPO) has shown good progress through its three-day subscription period. The ₹37.67 crore IPO has witnessed growing demand, with subscription rates opening at 0.22 times on day one, rising to 0.64 times on day two, and reaching 1.79 times by 5:24:33 PM on the final day, demonstrating solid investor interest in this contract manufacturing company for pharmaceutical and cosmetic products that serves companies both within India and internationally, manufacturing antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynaecological issues, and infections.

Astonea Labs IPO non-institutional investors segment leads with an impressive 5.60 times subscription, while retail investors show solid participation at 1.69 times and qualified institutional buyers at 0.70 times, reflecting investor confidence in this company that manufactures and markets pharmaceutical and cosmetic products under its brands "Glow Up" and "Regero," and exports to countries like Iraq and Yemen with 217 employees as of August 2024.

Astonea Labs IPO subscription reached a solid 1.79 times on the final day, led by NII (5.60x), Retail (1.69x) and QIB (0.70x). Check the details at 5paisa.
 

Subscription Status of Astonea Labs IPO:

Here are the subscription details for Astonea Labs IPO as of Day 3 (May 29, 2025, 5:15:00 PM):

Key Highlights - Day 3:

• Overall subscription reaching solid 1.79 times, showing strong growth from day two's 0.64 times
• NII segment leading with impressive demand at 5.60 times, significantly up from day two's 2.28 times
• Retail investors demonstrating good interest at 1.69 times, more than double day two's 0.68 times
• QIB segment showing improved participation at 0.70 times, up from day two's 0.11 times
• Total applications reached 2,190, indicating good investor participation
• The cumulative bid amount reached ₹63.815 crores
• Final day demonstrating strong confidence in the pharmaceutical contract manufacturing sector
• NII leadership reflecting high net-worth investor interest in pharma and cosmetic manufacturing
• Strong retail participation shows confidence in the export-oriented pharmaceutical business model

Astonea Labs IPO - Day 2 Subscription at 0.64 Times

Key Highlights - Day 2:

• Overall subscription rising to 0.64 times, showing significant improvement from day one's 0.22 times
• NII segment showing strong growth at 2.28 times, more than triple day one's 0.65 times
• Retail investors showing increased interest at 0.68 times, nearly double day one's 0.35 times
• QIB segment showing initial participation at 0.11 times, up from zero on day one
• Second day momentum indicates growing investor confidence in the pharmaceutical sector
• Contract manufacturing expertise attracting increased investor attention
• Second day, setting the foundation for a strong final day acceleration

Astonea Labs IPO - Day 1 Subscription at 0.22 Times

Key Highlights - Day 1:

• Overall subscription opening at 0.22 times, showing initial investor interest
• NII segment beginning at 0.65 times, indicating early high net-worth investor confidence
• Retail investors showing initial interest at 0.35 times on day one
• The QIB segment is yet to show participation at 0.00 times on the first day
• Opening day demonstrates early investor engagement in the contract manufacturing sector
• Initial momentum reflecting the assessment of the pharmaceutical and cosmetic manufacturing opportunity
• Contract manufacturing expertise drawing initial investor attention
• First day, setting the foundation for subsequent strong growth

About Astonea Labs IPO

Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally. The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynaecological issues, infections, and more.

The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for the pharmaceutical and cosmetic industries. The company markets its brands, "Glow Up" skincare and "Regero" pharma products, with plans to launch "Avicel," and exports to countries like Iraq and Yemen. As of August 2024, the company had 217 employees on payroll.

Financial performance shows steady growth with revenue increasing from ₹30.17 crores in FY2022 to ₹80.29 crores in FY2024, while profit after tax rose from ₹0.25 crores to ₹3.81 crores during the same period. For the nine months ended December 2024, the company reported revenue of ₹69.69 crores with PAT of ₹4.10 crores. The company maintains strong profitability metrics with 37.86% ROE, 22.95% ROCE, and 31.83% RONW.

Highlights of the Astonea Labs IPO:

• IPO type: Book Building IPO
• IPO size: ₹37.67 crores
• Fresh Issue: 27.90 lakh shares
• Face value: ₹10 per share
• Issue price band: ₹128 to ₹135 per share
• Lot size: 1,000 shares
• Minimum investment for retail investors: ₹1,35,000
• Minimum investment for HNI: ₹2,70,000 (2 lots)
• Market maker reservation: 1,44,000 shares
• Listing at: BSE SME
• IPO opens: May 27, 2025
• IPO closes: May 29, 2025
• Allotment date: May 30, 2025
• Listing date: June 3, 2025